Please login to the form below

Not currently logged in

orphan medicines

This page shows the latest orphan medicines news and features for those working in and with pharma, biotech and healthcare.

Beneluxa: the future of European market access?

Beneluxa: the future of European market access?

However there is one specialist area in which there is unquestionably a growing appetite for European greater collaboration: health technology assessment of innovative medicines. ... and has so far focused on appraising high cost orphan medicines.

Latest news

  • Orphan drugs from Biogen and Amicus win UK Prix Galien Orphan drugs from Biogen and Amicus win UK Prix Galien

    There was a much warmer welcome at the awards, hosted by ValueBase, for the pharma and biotech companies with products on the shortlist, which was dominated by orphan medicines. ... All bar one of the finalists were medicines for orphan conditions, and

  • EMA forges closer ties with HTA umbrella group EMA forges closer ties with HTA umbrella group

    The EMA has extended a partnership with the organisation representing Europe’s health technology assessment (HTA) bodies, aimed at improving access to medicines, for another three years. ... Other projects will look at how the regulator and HTAs define

  • The future of biotech The future of biotech

    IMS data for 2015 highlighted that six out of ten of the world's best-selling medicines were biologics: $18bn for Harvoni, a new medicine; $15bn for Humira and $6bn for ... In the US there may be federal developments. In the UK it has led to fragmented

  • Orphan drugs: Leading the way in patient-centricity Orphan drugs: Leading the way in patient-centricity

    So how do companies successfully engage with patients and ensure the orphan drug they have in development will reach the patients who need it? ... A recent paper concluded that: 'In practice, this implies a need for more systematic and meaningful

  • Surviving Brexit Surviving Brexit

    The product may then be sold throughout the EU. This route is compulsory for most biotechnology products and orphan medicines and is generally followed with other high technology products. ... Similarly, a sponsor of a medicine with orphan drug

More from news
Approximately 2 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Shoring up the framework Shoring up the framework

    Consequently pharmaceutical companies that hold marketing authorisations for centrally authorised medicines will be required to take certain steps. ... Marketing authorisation holders for medicines, including orphan drugs, must be established in the EU

  • Brexit: Implications for the pharma industry Brexit: Implications for the pharma industry

    Similarly, orphan drug designations currently need to be held by an EU-based entity. ... If the UK ends up outside the EEA, it may, like other non-EEA countries, put in place reduced assessment processes for products categorised as orphan drugs by the

  • A rare talent A rare talent

    Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment. ... The latter, says Sebastian, is “a very good first step, in terms of recognising that there is a difference when it comes to

  • Market access improvements in Turkey Market access improvements in Turkey

    Almost the entire pharmaceutical market is made up of prescription medicines (93.8%) with 87% reimbursed. ... While welcoming the promise of a slight acceleration of review time with high priority medicines, industry is disappointed that orphan drugs and

  • Tracking comms trends: Europe in the global vanguard on value Tracking comms trends: Europe in the global vanguard on value

    For example, last year the three Benelux countries signed a statement of intent to jointly procure orphan medicines in an effort to lower prices. ... More locally, US HMOs and insurance funds are using levels of HTA and deploying cost containment

More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...